Open Menu
Topic: Drug substance

Insight & Resources

Webinar

From Orphan Drugs to Oncology: CDMO Capabilities to Accelerate Small Molecule Development

Pharmaceutical companies of all sizes are often challenged to identify a CDMO partner that can truly grow with their candidates in early development. An organization may kick off drug development with one proposed indication and smaller production volumes in mind but, as clinical results emerge and indications are added, additional API demands may begin to outstrip their partner’s capacity.

For drug developers commercializing orphan drugs, the search to find small-scale commercial partners presents another unique challenge. Over the past two years, the FDA has approved more orphan drugs than non-orphan drugs, often with fast-track status. To meet this need, CDMOs must be able to scale quickly within their facilities to help their clients progress therapies from early clinical toward validation and commercial launch.

Cambrex recently invested $30 million in the expansion of its API development and small-scale commercial capabilities in High Point, North Carolina. On this webinar, Brian Swierenga, VP of Operations and Site Director, High Point and Dan Bowles, Senior Director of Chemical Development, High Point, discuss how their facility and the Cambrex network are evolving to enhance capabilities and accelerate API development.

Speakers

Brian Swierenga, Vice President, Operations and Site Director, High Point (North Carolina)

Brian Swierenga, Vice President, Operations and Site Director, High Point (North Carolina)

Dan Bowles, Senior Director, Chemical Development, High Point (North Carolina)

Dan Bowles, Senior Director, Chemical Development, High Point (North Carolina)